4

Background
Cancer vaccines aim to induce immunity specific to protein antigens that are differentially expressed by cancer cells relative to the normal cells from which they are derived. Through its network of specialized antigen presenting and effector cells, the immune system has the ability to become activated to recognize and lyse cancer cells. Current vaccine strategies aim to provide a series of signals that activate and mature dendritic cells (DC) for efficient antigen processing and presentation which in turn activate effector cells of the adaptive immune response. Listeria monocytogenes (Lm)-based vaccine vectors directly target and activate DCs in vivo, but in addition, take advantage of the capability of immunogenic infectious vectors to stimulate both adaptive and innate immune responses. Lm is an intracellular bacterium that has access to both class I and class II antigen processing pathways. Lm provides a potent stimulation of innate immunity and also stimulates an adaptive immune response through recruitment and activation of CD4 + and CD8 + T cells specific for encoded heterologous antigens (1) (2) (3) (4) . The ability of Lm to stimulate adaptive immunity is mainly based on its intracellular lifecycle and the ability to target DCs in vivo (4) . ANZ-100 is a live-attenuated double deleted Lm strain (LADD; Lm ΔactA/ΔinlB). This strain has deletions of two virulence genes, actA and internalin B (InlB).
These virulence-determinants facilitate cell-to-cell spread and invasion of non-phagocytic cells, and their combined deletion results in 1,000-fold attenuation when compared to wild-type Lm (5) . However, uptake of ANZ-100 by phagocytic cells in the liver and spleen is retained and results in a local proinflammatory cytokine response resulting in activation and recruitment of both innate and adaptive effector cells. This immune response results in delay in tumor growth and increased survival of mice bearing hepatic metastases (6, 7) . Importantly, multiple doses of Lm further extend survival.
The LADD strain has also been engineered to express human mesothelin and the resulting strain has been termed CRS-207 (Lm-mesothelin). CRS-207 has been shown to efficiently deliver mesothelin antigen into both class I and class II antigen processing pathways. Mesothelin is a tumor-associated antigen present on normal mesothelial cells and highly expressed by many human tumor types, including mesotheliomas, pancreatic adenocarcinomas (PDA), non-small cell lung cancers (NSCLC), and ovarian cancers (8) (9) (10) (11) (12) (13) (14) (15) (16) . This expression profile, combined with limited expression on the surface of normal tissues, makes mesothelin an attractive target for active tumor-specific immunotherapy.
Support for mesothelin as a T cell target comes from studies demonstrating a correlation between positive clinical outcomes and the induction of mesothelin-specific cellular immunity in subjects with PDA following vaccination with an irradiated allogeneic whole cell vaccine encoding granulocytemacrophage colony-stimulating factor (GM-CSF). In a Phase 1 study, a dose-dependent systemic antitumor response was reported to be associated with anti-mesothelin CD8 + T cell responses (17, 18) . In
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Author Manuscript Published OnlineFirst on December 6, 2011; DOI: 10.1158/1078-0432.CCR- subsequent studies, the induction of mesothelin-specific T cells as well as the increased postvaccination diversity and avidity of the T cell repertoire were shown to be associated with improved disease-free (DFS) and overall survival (OS) (19, 20) . Furthermore, CRS-207 mediates the induction of mesothelin-specific T cell responses that correlate with tumor regressions of mesothelin-expressing murine tumors (unpublished data).
A single intravenous (IV) dose of ANZ-100 underwent evaluation in a Phase 1 dose escalation study of safety and tolerability in adults with carcinoma and liver metastases (NCT00327652). A total of nine subjects received single-dose infusions at three dose levels (1x10 6 , 3x10 7 , 3x10 8 , and 1x10 10 cfu). Here, we report the safety, shedding and clearance data, clinical activity, and the induction of immunologic responses to both ANZ-100 and CRS-207.
SUBJECTS AND METHODS
Construction of ANZ-100 and CRS-207
ANZ-100 (LADD; Lm ΔactA/ΔinlB), Lm strain CERS 382.20, was constructed by deletion of the actA and inlB genes from the Streptomycin resistant wild-type strain DP-L4056. Using standard techniques, deletions of actA and inlB were made by homologous recombination of the mutant alleles into the wild-type chromosome (21) . Deletion mutations were confirmed by PCR. 
Study Design
Research. Nine subjects were enrolled into the ANZ-100 study at Johns Hopkins University (JHU) and Mary Crowley Cancer Center between 10/9/06 and 1/7/08. The primary objective of the ANZ-100 study was to determine the maximum tolerated dose (MTD) of a single dose of ANZ-100 in subjects with carcinoma and liver metastases. Using a standard 3+3 design, eligible subjects received a single 2-hour IV infusion of ANZ-100 (22) .
Seventeen subjects were enrolled into the CRS-207 study at JHU, the National Cancer Institute (NCI), the University of Pennsylvania, Hadassah-Hebrew University Medical Center, and at Mary Crowley Cancer Center between 12/13/07 and 1/5/09. The primary objective of the CRS-207 study was to determine the MTD of multiple doses of CRS-207 in subjects with malignancies known to express mesothelin. Secondary objectives included assessing safety, biodistribution and clearance of Lm, immunologic endpoints, and antitumor activity. Using a 3+3 design, sequential cohorts of 3-6 subjects received up to 4 doses of CRS-207 administered 3 weeks apart.
These multi-institutional, first in-human, Phase 1, dose-escalation studies were reviewed and approved by local institutional review boards, institutional biosafety committees, the Food and Drug Administration, and the NIH Recombinant DNA Advisory Committee. All participating subjects signed informed consent.
Subject Selection
In the ANZ-100 study, eligible subjects had treatment-refractory carcinoma and hepatic metastases. In the CRS-207 study, eligible subjects had treatment-refractory mesothelioma, PDA, NSCLC or ovarian cancer. For both studies, main eligibility criteria included: no cancer therapy for 4 weeks, age > 18 years old, a life expectancy of > 12 weeks, an Eastern Cooperative Oncology Group performance status of 0-1 or Karnofsky Performance Status of 80% to 100%, adequate organ function, no ongoing infections, history of brain metastases, or history of autoimmunity. Concurrent antineoplastic therapies, history of listeriosis or vaccination with a Lm-based vaccine, known allergy to both penicillin and sulfa, and artificial implants (except biliary stents) were not permitted. Subjects who were HIV, HTLV-1, HCV, or HBV positive were excluded.
Procedures and Treatment
Tests were performed for baseline toxicity (complete blood counts and chemistry profile) and tumor assessment (computerized tomography scan). The intervention and data collection schedules are shown in Supplemental Figures 1 (ANZ-100) and 2 (CRS-207).
Nine subjects (6 with colorectal cancer (CRC), 2 with PDA, 1 with melanoma) with treatmentrefractory carcinoma and liver metastases received a single-dose 2-hour infusion at one of three dose
Research. 
Assessments
Toxicities
Adverse events (AEs) were graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Initially, a dose-limiting toxicity (DLT) was defined as the occurrence of any NCI CTCAE (Version 3.0) > grade 3 that were determined to be possibly or probably related to the agent, during the 28 days after the first dose. For individuals who had ALT, AST or alkaline phosphatase elevations < grade 1 severity at study entry, a DLT was defined as enzyme elevations > 5× upper limit normal (ULN) that were determined to be related and persisted for > 7 days. For individuals who had ALT, AST or alkaline phosphatase levels that were > 2.5× to 3.5× ULN at study entry, a DLT was defined as enzyme elevations > 10× ULN that were determined to be related and persisted for > 7
days. Early initiation of antibiotics coincident with isolation of Lm from a sterile body site, other than blood (e.g., CSF, joint fluid) was considered a DLT. DLT criteria were modified several times during the CRS-207 study. In addition to the liver enzyme criteria mentioned, a DLT was defined as a treatmentrelated > grade 3 laboratory abnormality lasting > 48 hours, fever of > 40°C lasting greater than 24
hours, hypotension unresponsive to IV fluids, and grade 4 lymphocyte decreases that persisted for > 4 days. The MTD was the highest dose at which no more than one of six subjects experienced a DLT.
Shedding and Clearance
Specimens were obtained for culture in order to assess the Lm distribution and clearance. With each administration of ANZ-100, blood, urine, stool and sputum specimens were cultured at baseline, 6
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Immunologic Assessments
Multiplexed serum chemokine assay. Chemokines were detected using a custom Cytokine Bead Array Multiplexed serum cytokine assay. Cytokines were detected using the Meso Scale Discovery (MSD) platform (Gaithersburg, MD) using frozen serum samples collected before, 4 hours and 24 hours post infusion with ANZ-100 or CRS-207. ANZ-100 samples were tested using a 9-plex pro-inflammatory kit (GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, tumor necrosis factor-α (TNF-α)) and CRS-207 samples were tested using a 7-plex kit (IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF-α). Upon collection of all samples within a patient cohort, samples were tested by a blinded operator. Results are expressed as mean ± standard deviation.
Lymphocyte counts. For the ANZ-100 study, a BD FACS Calibur was used to determine absolute numbers of lymphocyte subpopulations after applying BD Multitest TM CD3/CD16, CD56/CD45/CD19
with Trucount, and BD Multitest TM CD3/CD8/CD45/CD4 with Trucount reagent cocktails.
Determination of cellular activation. For the ANZ-100 study, a BD FACS Calibur was used to determine the expression level of CD38 on NK cells in blood using CD3-FITC, CD38-PE, CD4-PerCp, CD16-APC, CD56 APC; and IgG Isotype-PE. CD38 expression levels were analyzed by a blinded operator and
Research. reported as a ratio of peak CD38 MESF value between 48h and 96h post dosing and pre-dose value.
A histogram is also presented for subject 001-005.
Detection of antigen-specific T cells. Peripheral blood mononuclear cells (PBMC) were prepared within 4-6 hours post collection and cryopreserved at each clinical site.
Detection of LLO-specific T cells by IFNγ-ELISPOT.
PBMCs were analyzed using a 2-step IFN-γ ELISPOT assay in which first autologous DCs were obtained through in vitro culture (23) . Monocytes were isolated from PBMCs using a one hour adherence step. Non-adherent cells were collected and cryopreserved. Adherent cells were cultured for two days in DC induction medium (RPMI with 1% autologous plasma and GM-CSF and IL-4) and then a cocktail containing IL-1β, IL-6 and prostaglandin E2-α(24). After two days of culture, mature DCs were harvested, counted and added at a 1:10 ratio to 2x10 5 non-adherent thawed PBMC. Antigen was added as pools of 15-mer peptides whose sequences overlap by 11 amino acids and cover the entire sequence of the Listeriolysin O (LLO), a 130 amino acid protein (25, 26) . The CEF pool was used as a positive control. The CEF is a pool of 32 peptides of defined CD8 + epitopes against CMV, EBV, and Influenza (27) . Cells were cultured for 24 hours in RPMI containing 10% human AB serum before they were washed and spots visualized using BD Biosciences'
Human IFN-γ Elispot and AEC substrate kits. Spots were enumerated in an Elispot reader (CellularTechnology, Ltd., Shaker Heights, OH) and analyzed using a software package (Immunospot software v. 3.6). T cell responses to LLO were considered positive when specific T cell frequencies were > 1 in 10 5 PBMCs and increased by at least 2-fold compared to baseline.
Detection of mesothelin-specific T cells by IFNγ-ELISPOT.
The methodology for the synthesis of peptides, ELISA assay for identifying reactive mesothelin peptides, and ELISPOT assays have previously been described (18) (19) (20) . Samples were tested from subjects with HLA-A1, A2, A3, and A24
alleles if pre-and post-treatment samples were available. T cell responses to mesothelin were considered positive when the frequency of specific responses were > 1 in 10 5 CD8 + peripheral blood lymphocytes (PBL) above the control sample and increased by at least 2-fold compared to baseline.
The maximal response to a single best peptide is reported.
Statistical Considerations
The main objectives of these studies were to determine the MTD of ANZ-100 or CRS-207 in subjects with cancer. A standard 3+3 design was used for dose escalation (22) . 
RESULTS
Subject Characteristics
Subject characteristics for both studies are shown in Table 1 . For ANZ-100, 6 subjects with CRC, 2 with PDA, and one with melanoma received a single dose of either 10 
Treatment-Related Toxicities and Dose Limiting Toxicity Events
A detailed description of treatment related grade > 2 toxicities for both studies is provided in Supplemental Table 1 . ANZ-100 was well-tolerated at all dose levels. The most frequent AEs of any grade were transient grade < 3 lymphopenia (9 pts, 100%), grade < 3 hyperglycemia (8 pts, 89%), hypophosphatemia (5 pts, 56%), and fever (7 pts, 78%). No DLTs were observed and ANZ-100 was well tolerated up to the maximum planned dose.
CRS-207 was also well tolerated. The most frequent AEs of any grade were transient lymphopenia (17 pts, 100%), hypophosphatemia (6 pts, 35%), transaminitis (7 pts, 41%), fever (9 pts, 53%), chills/rigors (9 pts, 53%), nausea (9 pts, 53%), fatigue (6 pts, 35%), and hypotension (6 pt, 35%). All of these AEs Following dosing of 3 subjects in Cohort 2 (1×10 9 cfu) without reaching a DLT, one subject was dosed in Cohort 3 at 1×10 10 cfu dose. This subject experienced a grade 2 cytokine release syndrome requiring aggressive fluid resuscitation. Due to the nature of the event, this was considered a DLT and the dose level was considered too toxic for further recruitment. The MTD was determined to be 1x10 9 cfu. To better characterize toxicities, additional subjects were enrolled into cohort 2 (1x10 9 cfu, n=3+3=6). Manageable hypotension and modest elevations in liver function tests (LFTs) were
observed. An intermediate dose of 3x10 8 cfu was also added. Four subjects were enrolled into this cohort before the study was terminated. Manageable hypotension and transient LFT elevations (3 of 4 subjects) was also observed at the new dose level. One subject had elevations up to 11x ULN after a second dose in the absence of any changes in bilirubin. The LFTs improved without intervention. The subject was not re-dosed.
In general, subjects treated at all dose levels experienced symptoms that might be expected from a cytokine release-like syndrome from a bacteremia. While not all subjects experienced the same events, a constellation of symptoms was common. Lm was administered IV over a 2 hour period.
Subjects typically had a temperature peak at 2-4 hours, sometimes associated with rigors, nausea, headaches, dehydration, and dry mouth. Mild hypotension was self-correcting or corrected with IV fluids. The most consistent laboratory abnormalities were transient, self-correcting electrolyte abnormalities and lymphopenias with nadirs at 4 hour post infusion. The degree of lymphopenia was dose-dependent and the most significant hypotension occurred at the highest dose level. The transient, self-correcting nature suggests that these abnormalities are the result of electrolytes and lymphocytes transiently shifting out of the blood compartment. Overall review of the safety data from the trial did not identify any significant toxicity with Lm or Lm-mesothelin that was not reversible or unexpected from either previous studies in cynomologus monkeys or based on mechanism of action.
Shedding and clearance
ANZ-100 was not detected in the blood, stool, urine, or sputum specimens collected at any time point.
Lm suspected to be CRS-207 was detected in blood cultures of four subjects. In 2 of the subjects, the cultures were negative by 24 hours. An ovarian cancer subject who received a dose of 1x10 8 cfu had positive cultures at 4 and 24 hours after the first IV infusion. Subsequent blood cultures 4 days after dosing were negative. Blood cultures taken after her second infusion were negative. Lm suspected to be CRS-207 was detected in blood cultures of a mesothelioma subject receiving 1x10 9 cfu at day 4 after the second IV infusion. Subsequent cultures were negative. All remaining blood, stool, or urine specimens collected throughout the study for all subjects were negative.
Immunohistochemistry
Mesothelin membranous staining was detected in all 7 available archived samples for subjects enrolled into the CRS-207 study. The extent of staining is listed in Table 1 .
PBMC phenotype analysis after ANZ-100 administration
Peripheral blood was analyzed prior to treatment with ANZ-100, daily for 5 days following treatment, and then weekly for one month. Immune activation was determined by phenotypic analysis of NK cells (CD3 -CD16/56 + ). Interestingly, there was a transient reduction in peripheral lymphocyte and NK cell numbers ( Figure 1A, B) that reached a nadir at day 2 following treatment, suggesting the possibility that ANZ-100 induced activation results in lymphocyte and NK cell margination from the peripheral blood to other compartments. A significant upregulation of the activation marker CD38 was noted on NK cells for all dose levels (p = 0.0008, Figure 1C ). There appears to be a dose-dependent trend but it was not statistically significant (p = 0.1238). This level increased at the 96-hour time point as shown for one patient ( Figure 1D ).
Cytokine/chemokine induction after ANZ-100 and CRS-207 administration
Serum samples were collected prior to and at 2 hours, 6 hours, and daily for 5 days following ANZ-100 ( Figure 2C, D) . The upregulation of the CD38 activation marker suggests biologic activity of ANZ-100 at doses as low as 1x10 6 cfu. However, a more consistent induction of pro-inflammatory cytokines and chemokines was observed in subjects receiving the higher dose level of 3x10 8 cfu.
In the CRS-207 study, chemokine induction was noted for all dose levels including the starting dose level of 1x10 8 cfu. For MCP-1, MIP1-ß, and IP-10, the pattern was consistently elevated for all dose levels (p = 0.0050, p < 0.0001, and p < 0.0001, respectively) and did not vary significantly across time points (Figure 3A-C) . The degree of upregulation is less than that observed in the ANZ-100 study, which may be due to the fact that the levels were taken at 24 hours rather than at the expected 2-hour post infusion peak (Figure 3A-C 
Detection of LLO-specific and mesothelin-specific T cell responses after CRS-207 administration
LLO-specific T cell responses were analyzed in 8 subjects with viable samples pre-treatment and post the second and fourth infusion of CRS-207 ( Figure 4A ). Final T cell responses are reported. Six of the subjects were positive for vaccine-induced Lm-specific responses. The CEF-specific responses are provided in Supplemental Figure 3 . In the CRS-207 study, mesothelin-specific CD8 + T cell responses were induced in 6 of the 10 evaluable subjects (Figure 4B ).
Efficacy and survival
While the CRS-207 study enrolled subjects with multiple disease types and was not powered to assess survival, thirty-seven percent of this Phase 1 patient population survived for > 15 months, with 3 subjects alive as of October 14, 2010 ( Table 2 ). Of the 6 "long-term" survivors, 3 had PDA, 2 had NSCLC, and 1 had mesothelioma. These 6 subjects had prior immunotherapy or subsequent local radiation. Five of 6 subjects received all 4 doses of CRS-207 and all 5 evaluable subjects demonstrated vaccine-induced Lm-specific responses. One subject had been discontinued from study after 1 dose due to a protocol violation and samples were not collected for immunological evaluation.
In addition, 4 of the 5 evaluable subjects among the long-term survivors had stable disease by RECIST at day 91 (end of study). Eight out of 8 evaluable subjects in the group that survived < 15 months had progressive disease by day 91. All 5 evaluable subjects who lived > 15 months developed LLO responses. One additional subject lived > 15 months but was not tested because a post-treatment sample was not collected. Thus, the induction of LLO-specific T cell responses may serve as a biomarker of immune competency in future studies. In this small subset of 10 subjects with multiple histologic types of cancer, the induction of mesothelin-specific responses did not correlate with survival.
The induction of mesothelin-specific T cell responses as a marker of response to CRS-207 requires further investigation in a larger study of more homogenous subjects. These data provide the rationale for further evaluation of this Lm-mesothelin vaccine in a Phase 2 study. The transient transaminitis cases were expected based on mechanism of action and preclinical studies.
DISCUSSION
Another example of transaminitis in the context of immunotherapy is the flares in chronic hepatitis B patients induced by Peg-IFN α-2b (29) . Interestingly, host induced flares which were followed by HBV DNA decreases were highly associated with response. These flares are thought to be due to the stimulatory effect of IFN, which is capable of increasing T cell cytolytic activity and NK cell function.
Likewise, with Lm-based therapies, the transaminitis is likely to be inflammatory in nature and not necessarily a negative finding. This will be monitored in future studies. With the recent approval of Provenge for the treatment of metastatic castrate resistant prostate cancer, there is mixed enthusiasm and continued skepticism regarding vaccination as a treatment for cancer.
Provenge has been shown to prolong survival without evidence of appreciable RECIST response or prolongation of time to progression (30) . In addition, another recently approved immunotherapy, ipilimumab, an antagonist antibody to cytotoxic T lymphocyte associated-4 (CTLA-4), has also shown a survival benefit in melanoma despite 5.7-10.9% response rates (31) . In these studies, some subjects demonstrate increases in tumor volume before a delayed response and therefore response rate is likely to underestimate the activity of these agents. Therefore, OS is currently the best endpoint to evaluate immunotherapeutic agents in advanced cancer. While the survival data presented here is only hypothesis generating, it is provocative.
Conclusions
In summary, Lm-based vaccines, ANZ-100 and CRS-207, are well tolerated in subjects with advanced cancers. There is encouraging evidence of immune activation and potential clinical benefit, thus warranting further clinical studies. 
